Prostate cancer screening

Current Oncology Reports

Volumn 13, Issue 1, 2011, Pages 57-62

  Cook, Elise D ^a   Nelson, Ana C ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Cancer screening; Prostate cancer; Prostate cancer screening

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BRCA2 GENE; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; DIARRHEA; DIGITAL RECTAL EXAMINATION; DYSPNEA; EARLY DIAGNOSIS; FALSE POSITIVE RESULT; GYNECOMASTIA; HEART FAILURE; HIGH RISK PATIENT; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; IMPOTENCE; LIBIDO DISORDER; MASTALGIA; OSTEOPENIA; OVERALL SURVIVAL; PATIENT SELECTION; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PROSTATE BIOPSY; PROSTATE CANCER; RISK ASSESSMENT; SIDE EFFECT; TRANSRECTAL ULTRASONOGRAPHY; WEIGHT GAIN;

CLINICAL TRIALS AS TOPIC; EARLY DETECTION OF CANCER; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; UNITED STATES;

EID: 79551567630     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-010-0136-x     Document Type: Article

References (26)

1. J Hugosson S Carlsson G Aus, et al. 2010 Mortality results from the Goteborg randomized population-based prostate-cancer screening trial Lancet Oncol 11 725 732 10.1016/S1470-2045(10)70146-7 20598634 The Goteborg study's first report on cumulative prostate cancer incidence and mortality demonstrated a significant reduction in prostate cancer mortality over a 14-year period, and the benefit of prostate cancer screening compared favorably to that of other cancer screenings
2. FH Schroder J Hugosson MJ Roobol, et al. 2009 Screening and prostate-cancer mortality in a randomized European study N Eng J Med 360 1320 1328 10.1056/NEJMoa0810084 Data from the ERSPC trial showed that PSA-based screening decreased the prostate cancer-related mortality rate by 20%
3. A Jemal R Siegel J Xu E Ward 2010 Cancer Statistics 2010 CA Cancer J Clin 60 277 300 10.3322/caac.20073 20610543
4. National Cancer Institute, US National Institutes of Health: Cancer advances in focus: prostate cancer. Available at http://www.cancer.gov/ cancertopics/cancer-advances-in-focus/prostate. Accessed July 19, 2010.
5. WJ Catalona DS Smith TL Ratliff, et al. 1991 Measurement of prostate-specific antigen in serum as a screening test for prostate cancer N Eng J Med 324 1156 1161 1:STN:280:DyaK3M7oslSksA%3D%3D 10.1056/NEJM199104253241702
6. A Wolf RC Wender RB Etzioni, et al. 2010 American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010 CA Cancer J Clin 60 70 98 10.3322/caac.20066 20200110
7. National Cancer Institute, US National Institute of Health: What you need to know about prostate cancer: risk factors. Available at http://www.cancer. gov/cancertopics/wyntk/prostate/page4. Accessed July 19, 2010.
8. Mills GB, Reiger PT: Genetic predisposition to breast cancer. In Breast Cancer. Edited by Hunt KK, Robb GL, Strom EA, Ueno NT. New York: Springer-Verlag; 2001:55-82.
9. IM Thompson DP Ankerst C Chi, et al. 2006 Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial J Natl Cancer Inst 98 529 534 10.1093/jnci/djj131 16622122 (Pubitemid 43898816)
10. GL Andriole ED Crawford RL Grubb, et al. 2009 Mortality results from a randomized prostate-cancer screening trial N Eng J Med 360 1310 1319 1:CAS:528:DC%2BD1MXjs1ejsLk%3D 10.1056/NEJMoa0810696 The PLCO cancer screening trial in the United States did not demonstrate a statistically significant reduction in prostate cancer-related mortality in men randomized to receive PSA and DRE screening
11. L Esserman Y Shieh I Thompson 2009 Rethinking screening for breast cancer and prostate cancer JAMA 302 1685 1692 1:CAS:528:DC%2BD1MXhtlWqs7%2FO 10.1001/jama.2009.1498 19843904
12. G Draisma R Etzioni A Tsodikov, et al. 2009 Lead time and over-diagnosis in prostate-specific antigen screening: importance of methods of context J Natl Cancer Inst 101 374 383 10.1093/jnci/djp001 19276453
13. M Hakama MP Coleman DM Alexe A Auvinen 2008 Cancer screening: evidence and practice in Europe 2008 Eur J Cancer 44 1404 1413 10.1016/j.ejca.2008.02.013 18343653
14. ML Essink-Bot HJ de Koning HG Nijs, et al. 1998 Short term effects of population-based screening for prostate cancer on health-related quality of life J Natl Cancer Inst 90 925 931 1:STN:280:DyaK1c3pvFaisQ%3D%3D 10.1093/jnci/90.12.925 9637143
15. FJ Fowler Jr MJ Barry B Walker-Corkery, et al. 2006 The impact of suspicious prostate biopsy on patients' psychological, socio-behavioral, and medical care outcomes J Gen Intern Med 21 715 721 10.1111/j.1525-1497.2006. 00464.x 16808772 (Pubitemid 43973556)
16. RO Roberts EJ Bergstralh JA Besse, et al. 2002 Trends and risk factors for biopsy complications in the pre-PSA and PSA eras, 1980 to 1997 Urology 59 79 84 10.1016/S0090-4295(01)01465-0 11796286 (Pubitemid 34059311)
17. B Djavan A Zlotta M Remzi, et al. 2000 Optimal predictors of cancer on repeat prostate biopsy: a prospective study of 1,051 men J Urol 163 1144 1148 1:STN:280:DC%2BD3c7pvFOntw%3D%3D 10.1016/S0022-5347(05)67711-7 10737484 discussion 1148-1149
18. JC Hu 2009 Gu Xiangmei GU, Lipsitz SR, et al.: Comparative effectiveness of minimally invasive vs open radical prostatectomy JAMA 302 1557 1564 1:CAS:528:DC%2BD1MXht1KnurvO 10.1001/jama.2009.1451 19826025
19. SP Elliot MV Meng EP Elkin, et al. 2007 Incidence of urethral stricture after primary treatment for prostate cancer: data from CaPSURE J Urol 178 529 534 10.1016/j.juro.2007.03.126 discussion 534 (Pubitemid 47030504)
20. National Cancer Institute, US National Institutes of Health: What you need to know about prostate cancer: treatment. Available at http://www.cancer. gov/cancertopis/wyntk/prostate/page8. Accessed July 19, 2010.
21. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection v.2.2010. Available at http://www.nccn.org. Accessed August 5, 2010.
22. SJ Eyre DP Ankerst JT Wei, et al. 2009 Validation in a multiple urology practice cohort of Prostate Cancer Prevention Trial calculator for predicting cancer detection J Urol 182 2653 2658 10.1016/j.juro.2009.08.056 19836788
23. DJ Parekh DP Ankerst BA Higgins, et al. 2006 External validation of the Cancer Prevention Trial risk calculator in screened population Urology 68 1152 1155 10.1016/j.urology.2006.10.022 17169636 (Pubitemid 44880388)
24. DP Ankerst J Groskopt JR Day, et al. 2008 Predicting prostate cancer risk through incorporation of cancer gene 3 J Urol 180 1303 1308 10.1016/j.juro.2008.06.038 18707724 discussion 1308
25. HB Carter JD Pearson EJ Metter, et al. 1992 Longitudinal evaluation of prostate-specific antigen levels in men with and without disease JAMA 267 2215 2220 1:STN:280:DyaK383htFOrtQ%3D%3D 10.1001/jama.267.16.2215 1372942
26. HB Carter L Ferrucci A Kettermann, et al. 2006 Detection of life-threatening cancer with prostate-specific antigen velocity during a window of curability J Natl Cancer Inst 98 1521 1527 10.1093/jnci/djj410 17077354 (Pubitemid 44680903)